Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Reply: Multivessel Versus Culprit-Vessel PCI in Patients With NSTEMI and Cardiogenic Shock

  • Mohamed A. Omer
  • , Emmanouil S. Brilakis
  • , Islam Y. Elgendy
  • , Paul S. Chan
  • , John A. Spertus

Producción científica: Letterrevisión exhaustiva

Idioma originalEnglish
Páginas (desde-hasta)1851-1852
Número de páginas2
PublicaciónJACC: Cardiovascular Interventions
Volumen14
N.º16
DOI
EstadoPublished - ago 23 2021

Financiación

Dr Omer has reported that he has no relationships relevant to the contents of this paper to disclose. Dr Brilakis has received consulting fees and/or speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor, Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; is an owner of Hippocrates; and is a shareholder of MHI Ventures. Dr Elgendy has received research grants from Caladrius Biosciences unrelated to this manuscript content. Dr Chan is supported by a grant from the National Heart, Lung, and Blood Institute (1R01HL123980). Dr Spertus has received grant funding from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Abbott Vascular, and Bayer; has an equity interest in Health Outcomes Sciences; has a copyright to the Seattle Angina Questionnaire; and has served as a consultant to Novartis, Bayer, United Healthcare, and AstraZeneca. Dr Omer has reported that he has no relationships relevant to the contents of this paper to disclose. Dr Brilakis has received consulting fees and/or speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor, Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; is an owner of Hippocrates; and is a shareholder of MHI Ventures. Dr Elgendy has received research grants from Caladrius Biosciences unrelated to this manuscript content. Dr Chan is supported by a grant from the National Heart, Lung, and Blood Institute (1R01HL123980). Dr Spertus has received grant funding from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Abbott Vascular, and Bayer; has an equity interest in Health Outcomes Sciences; has a copyright to the Seattle Angina Questionnaire; and has served as a consultant to Novartis, Bayer, United Healthcare, and AstraZeneca.

FinanciadoresNúmero del financiador
Caladrius Biosciences Inc
Cardiovascular Innovations Foundation
MHI Ventures
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)1R01HL123980
AMGen
AstraZeneca
Siemens USA
Medtronic
Center for Social Inclusion
Patient-Centered Outcomes Research Institute
GE Healthcare
Boston Scientific Neuromodulation Corporation
Abbott Vascular
Bayer Fund
InfraReDx
Biotronik Incorporated

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Huella

    Profundice en los temas de investigación de 'Reply: Multivessel Versus Culprit-Vessel PCI in Patients With NSTEMI and Cardiogenic Shock'. En conjunto forman una huella única.

    Citar esto